Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
- 1 January 2005
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 45 (2), 185-197
- https://doi.org/10.1016/j.jacc.2004.10.031
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Types of Change in Coronary Stenosis Severity and Their Relative Importance in Overall Progression and Regression of Coronary DiseaseAnnals of the New York Academy of Sciences, 2006
- Epidemic Obesity and the Metabolic SyndromeCirculation, 2003
- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 2003
- Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary DiseaseNew England Journal of Medicine, 2001
- Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL CholesterolArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL CholesterolCirculation, 2001
- Effect of Statins on Risk of Coronary DiseaseJAMA, 1999
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A MetabolismJCI Insight, 1979